NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
20 trialsNCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT02988440 2020-12-19
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Phase 1 Completed
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT02069145 2020-08-11
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Mereo BioPharma
Phase 1 Completed
NCT01498952 2019-02-19
MEDI-573-1028
MedImmune LLC
Phase 1 Completed
NCT00692770 2018-08-08
STORM
Bayer
Phase 3 Completed
NCT01839630 2017-12-20
SUCCESS
Bayer
Completed
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT01539681 2016-02-18
STELLA
Bayer
Completed
NCT01232296 2015-12-04
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Novartis
Phase 2 Completed
NCT00105443 2014-10-31
SHARP
Bayer
Phase 3 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00044512 2014-04-16
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00398814 2014-02-19
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00494299 2013-12-20
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Bayer
Phase 3 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed
NCT00712855 2012-10-30
HCC
GlaxoSmithKline
Phase 1 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated